Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor

摘要

To the Editor,The term plasma cell dyscrasia is used to describe an entire spectrum of disorders involving a neo-plastic proliferation of plasma cells and an exces-sive production of immunoglobulin. Multiple myeloma (MM) and Waldenstrom's macroglobin-emia (WM) are a part of spectrum of these dis-eases. The mean age of affected patients in both diseases is mia-60s. MM is a B-cell malig-nancy characterizea by the clonal expansion of tu-moral plasma cells in the bone marrow. The main clinical manifestations of the disease include pan-cytopenia, hyperproteinemia, renal dysfunction, bone lesions, and immunodeficiency . This pathology remains an incurable hematological malignancy despite novel therapeutic approaches involving the targeting of both AAM cells and bone marrow environment WM is a lymphoproliferative disorder characterized by a lymphoplasmacytic bone marrow infiltrate and high levels of a mono-clonal lgM in serum.